» Articles » PMID: 38883205

Dynamics of a Network Mediated by IL-36 and Involved in the Pathogenesis of Psoriasis

Overview
Date 2024 Jun 17
PMID 38883205
Authors
Affiliations
Soon will be listed here.
Abstract

The pathogenesis of the inflammatory, chronic, and common skin disease psoriasis involves immune cells, skin cells (keratinocytes), and the cytokines they secrete. Hyperproliferation and abnormal differentiation of keratinocytes are hallmarks of the disease. The roles of cytokines such as TNF, IL-15, IL-17, and IL-23 in psoriasis have been studied through mathematical/computational models as well as experiments. However, the role of proinflammatory cytokine IL-36 in the onset and progression of psoriasis is still elusive. To explore the role of IL-36, we construct a network embodying indirect cell-cell interactions of a few immune and skin cells mediated by IL-36 based on existing knowledge. We also develop a mathematical model for the network and perform a global sensitivity analysis. Our results suggest that the model is most sensitive to a parameter that represents the level of cytokine IL-36. In addition, a steady-state analysis of the model suggests that an increase in the level of IL-36 could lead to the hyperproliferation of keratinocytes and, thus, psoriasis. Our analysis also highlights that the plaque formation and progression of psoriasis could occur through either a gradual or a switch-like increase in the keratinocyte population. We propose that the switch-like increase would be due to a bistable behavior of the network toward either a psoriatic or healthy state and could be used as a novel treatment strategy.

References
1.
Gunther S, Sundberg E . Molecular determinants of agonist and antagonist signaling through the IL-36 receptor. J Immunol. 2014; 193(2):921-30. DOI: 10.4049/jimmunol.1400538. View

2.
Johnston A, Xing X, Wolterink L, Barnes D, Yin Z, Reingold L . IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017; 140(1):109-120. PMC: 5494022. DOI: 10.1016/j.jaci.2016.08.056. View

3.
Mercurio L, Morelli M, Scarponi C, Eisenmesser E, Doti N, Pagnanelli G . IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment. Cell Death Dis. 2018; 9(11):1104. PMC: 6207563. DOI: 10.1038/s41419-018-1143-3. View

4.
Vigne S, Palmer G, Lamacchia C, Martin P, Talabot-Ayer D, Rodriguez E . IL-36R ligands are potent regulators of dendritic and T cells. Blood. 2011; 118(22):5813-23. DOI: 10.1182/blood-2011-05-356873. View

5.
Dietrich D, Martin P, Flacher V, Sun Y, Jarrossay D, Brembilla N . Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines. Cytokine. 2016; 84:88-98. DOI: 10.1016/j.cyto.2016.05.012. View